Cargando…

Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19

BACKGROUND: People suffering from COVID‐19 are typically considered non‐infectious 14 days after diagnosis if symptoms have disappeared for at least 48 h. We describe three patients who independently acquired their infection. These three patients experienced mild COVID‐19 and completely recovered sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahn, Tobias, Mhedhbi, Ines, Hein, Sascha, Raupach, Jan, Miskey, Csaba, Husria, Younes, Bayanga, Kathrin, Bartel, Detlef, Vieths, Stefan, Ivics, Zoltan, Oberle, Doris, Keller‐Stanislawski, Brigitte, Herrlein, Marie‐Luise, Maier, Thorsten Jürgen, Hildt, Eberhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652783/
https://www.ncbi.nlm.nih.gov/pubmed/34637150
http://dx.doi.org/10.1111/all.15138
_version_ 1784611613760815104
author Zahn, Tobias
Mhedhbi, Ines
Hein, Sascha
Raupach, Jan
Miskey, Csaba
Husria, Younes
Bayanga, Kathrin
Bartel, Detlef
Vieths, Stefan
Ivics, Zoltan
Oberle, Doris
Keller‐Stanislawski, Brigitte
Herrlein, Marie‐Luise
Maier, Thorsten Jürgen
Hildt, Eberhard
author_facet Zahn, Tobias
Mhedhbi, Ines
Hein, Sascha
Raupach, Jan
Miskey, Csaba
Husria, Younes
Bayanga, Kathrin
Bartel, Detlef
Vieths, Stefan
Ivics, Zoltan
Oberle, Doris
Keller‐Stanislawski, Brigitte
Herrlein, Marie‐Luise
Maier, Thorsten Jürgen
Hildt, Eberhard
author_sort Zahn, Tobias
collection PubMed
description BACKGROUND: People suffering from COVID‐19 are typically considered non‐infectious 14 days after diagnosis if symptoms have disappeared for at least 48 h. We describe three patients who independently acquired their infection. These three patients experienced mild COVID‐19 and completely recovered symptomatically within 10 days, but remained PCR‐positive in deep pharyngeal samples for at least 38 days. We attempted to isolate virus from pharyngeal swabs to investigate whether these patients still carried infectious virus. METHODS: Infectious virus was amplified in Vero E6 cells and characterized by electron microscopy and WGS. The immune response was investigated by ELISA and peptide arrays. RESULTS: In all three cases, infectious and replication‐competent virus was isolated and amplified in Vero E6 cells. Virus replication was detected by RT‐PCR and immunofluorescence microscopy. Electron microscopy confirmed the formation of intact SARS‐CoV‐2 particles. For a more detailed analysis, all three isolates were characterized by whole‐genome sequencing (WGS). The sequence data revealed that the isolates belonged to the 20A or 20C clade, and two mutations in ORF8 were identified among other mutations that could be relevant for establishing a long‐term infection. Characterization of the humoral immune response in comparison to patients that had fully recovered from mild COVID‐19 revealed a lack of antibodies binding to sequential epitopes of the receptor‐binding domain (RBD) for the long‐term infected patients. CONCLUSION: Thus, a small portion of COVID‐19 patients displays long‐term infectivity and termination of quarantine periods after 14 days, without PCR‐based testing, should be reconsidered critically.
format Online
Article
Text
id pubmed-8652783
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86527832021-12-08 Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19 Zahn, Tobias Mhedhbi, Ines Hein, Sascha Raupach, Jan Miskey, Csaba Husria, Younes Bayanga, Kathrin Bartel, Detlef Vieths, Stefan Ivics, Zoltan Oberle, Doris Keller‐Stanislawski, Brigitte Herrlein, Marie‐Luise Maier, Thorsten Jürgen Hildt, Eberhard Allergy ORIGINAL ARTICLES BACKGROUND: People suffering from COVID‐19 are typically considered non‐infectious 14 days after diagnosis if symptoms have disappeared for at least 48 h. We describe three patients who independently acquired their infection. These three patients experienced mild COVID‐19 and completely recovered symptomatically within 10 days, but remained PCR‐positive in deep pharyngeal samples for at least 38 days. We attempted to isolate virus from pharyngeal swabs to investigate whether these patients still carried infectious virus. METHODS: Infectious virus was amplified in Vero E6 cells and characterized by electron microscopy and WGS. The immune response was investigated by ELISA and peptide arrays. RESULTS: In all three cases, infectious and replication‐competent virus was isolated and amplified in Vero E6 cells. Virus replication was detected by RT‐PCR and immunofluorescence microscopy. Electron microscopy confirmed the formation of intact SARS‐CoV‐2 particles. For a more detailed analysis, all three isolates were characterized by whole‐genome sequencing (WGS). The sequence data revealed that the isolates belonged to the 20A or 20C clade, and two mutations in ORF8 were identified among other mutations that could be relevant for establishing a long‐term infection. Characterization of the humoral immune response in comparison to patients that had fully recovered from mild COVID‐19 revealed a lack of antibodies binding to sequential epitopes of the receptor‐binding domain (RBD) for the long‐term infected patients. CONCLUSION: Thus, a small portion of COVID‐19 patients displays long‐term infectivity and termination of quarantine periods after 14 days, without PCR‐based testing, should be reconsidered critically. John Wiley and Sons Inc. 2021-10-24 2022-07 /pmc/articles/PMC8652783/ /pubmed/34637150 http://dx.doi.org/10.1111/all.15138 Text en © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Zahn, Tobias
Mhedhbi, Ines
Hein, Sascha
Raupach, Jan
Miskey, Csaba
Husria, Younes
Bayanga, Kathrin
Bartel, Detlef
Vieths, Stefan
Ivics, Zoltan
Oberle, Doris
Keller‐Stanislawski, Brigitte
Herrlein, Marie‐Luise
Maier, Thorsten Jürgen
Hildt, Eberhard
Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title_full Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title_fullStr Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title_full_unstemmed Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title_short Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
title_sort persistence of infectious sars‐cov‐2 particles for up to 37 days in patients with mild covid‐19
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652783/
https://www.ncbi.nlm.nih.gov/pubmed/34637150
http://dx.doi.org/10.1111/all.15138
work_keys_str_mv AT zahntobias persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT mhedhbiines persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT heinsascha persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT raupachjan persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT miskeycsaba persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT husriayounes persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT bayangakathrin persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT barteldetlef persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT viethsstefan persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT ivicszoltan persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT oberledoris persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT kellerstanislawskibrigitte persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT herrleinmarieluise persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT maierthorstenjurgen persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19
AT hildteberhard persistenceofinfectioussarscov2particlesforupto37daysinpatientswithmildcovid19